← Back to Search

CAR T-cell Therapy

CAR T-Cell Therapy for Esophageal Cancer

Phase 1

Recruiting

Led By Geoffrey Ku, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Life expectancy of ≥4 months

Diagnosis of pathologically confirmed EG adenocarcinoma

Must not have

Receiving therapy for concurrent active malignancy

Active interstitial lung disease/pneumonitis or a history of interstitial lung disease/pneumonitis requiring treatment with systemic steroids

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Summary

"This trial involves collecting white blood cells from participants, modifying them in a lab to become targeted CAR T cells, and then giving them back to the participants as a therapy. The whole process will take around

Who is the study for?

This trial is for individuals with certain types of cancer affecting the lining of organs, esophagus, or stomach. Participants must have T cells that can be collected and modified in a lab. Specific eligibility details are not provided but typically include factors like age, health status, and prior treatments.

What is being tested?

The study tests a new therapy where patients' own T cells are engineered to target cancer cells expressing mesothelin (MSLN). These modified T cells (M28z1XXPD1DNR CAR) are then given back to the patient to help fight the cancer.

What are the potential side effects?

While specific side effects aren't listed here, CAR T-cell therapies often cause immune system reactions such as fever, fatigue, headache, and can sometimes lead to more severe complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My doctor expects me to live for at least 4 more months.

Select...

I have been diagnosed with esophagogastric adenocarcinoma.

Select...

I am fully active or can carry out light work.

Select...

I am 18 years old or older.

Select...

I have received at least one treatment for my HER2 positive condition.

Select...

My cancer has worsened or I couldn't tolerate the treatment after at least one therapy.

Select...

My cancer has returned or spread to other parts of my body.

Select...

My tumor shows high MSLN levels.

Select...

My cancer is stage IV and has spread to the lining of my abdomen.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently being treated for another cancer.

Select...

I have or had lung inflammation that needed steroid treatment.

Select...

I do not have HIV or active hepatitis B or C infections.

Select...

I am taking 10 mg or more of prednisone daily or similar medications.

Select...

I have previously received CAR T cell therapy or another type of cellular therapy.

Select...

I have untreated brain metastases.

Select...

I have serious heart conditions or infections that are not under control.

Select...

I have had blood cancer treatment within the last 5 years.

Select...

I have had treatment targeting mesothelin before.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Maximum Tolerated Dose of M28z1XXPD1DNR CAR T cells

Number of treatment-emergent adverse events

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal CarcinomatosisExperimental Treatment1 Intervention

Participants will be diagnoses with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal Carcinomatosis

0 / 18Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,963 Previous Clinical Trials

597,386 Total Patients Enrolled

207 Trials studying Breast Cancer

83,999 Patients Enrolled for Breast Cancer

Geoffrey Ku, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

2 Previous Clinical Trials

108 Total Patients Enrolled

~12 spots leftby Sep 2028

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.